secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0000950170-25-108854
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics Q2 2025: net income $5.2M on derivative gain; CNSide assay launched in Texas
--------------------------------------------------------------------------------

- Cash $6.9M at June 30, 2025 vs $3.6M at Dec 31, 2024; operating loss $1.5M vs $3.7M in Q2 2024.
- Net income $5.2M ($0.02 diluted) vs net loss $2.9M ($0.45 loss) in Q2 2024; derivative gain of $6.5M pre-tax.
- CNSide CSF assay launched in Texas in Aug 2025; TAM estimated $6B; additional states planned late 2025-2026.
- REYOBIQ dose optimization trial started; FDA IND clearance for pediatric high-grade glioma and ependymoma.
- Received $1.6M advance from $17.6M CPRIT grant; added industry veteran Kyle Guse to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000095017025108854/0000950170-25-108854-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000095017025108854/pstv-20250814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-108854

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer